RxDoctor Payments Data

Stephan Pavlos, MD

Cardiovascular Disease · Salisbury, MDNPI 1619952439

Payments from drug & device makers

$1,560in general payments, 2019–2025

Across 75 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$543
  • Boehringer Ingelheim$169
  • Pfizer$139
  • E.r. Squibb & Sons, L.L.C.$138
  • Amgen$85
  • Edwards Lifesciences$77
  • plus $409 from 11 others

What the payments were for

  • Food & beverage$1,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,560 in reported general payments places this provider in the 45th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$628,010
Medicare patients
1,656
Services billed
6,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$331,741
XareltoRivaroxaban94$127,373
EntrestoSacubitril/Valsartan82$91,662
Repatha SureclickEvolocumab43$38,956
BrilintaTicagrelor31$20,559
JardianceEmpagliflozin14$19,398
Metoprolol Succinate374$6,494
Rosuvastatin Calcium195$6,471
Atorvastatin Calcium438$6,335
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,260
VascepaIcosapent Ethyl13$5,582
Ezetimibe35$3,869
Potassium Chloride95$3,483
Amiodarone Hcl94$2,851
Losartan Potassium186$2,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$331,741268 claims
Johnson & JohnsonXarelto$67$127,37394 claims
NovartisEntresto$42$91,66282 claims
AstraZenecaBrilinta$49$20,55931 claims
Boehringer IngelheimJardiance$169$19,39814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →